Med. praxi. 2011;8(10):410-414
Clinical pharmacology of profon pump inhibitors
- 1 Klinické a výzkumné centrum pro střevní záněty ISCARE a 1. LF UK, Praha
- 2 Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK, Praha
- 3 Interní klinika ÚVN a 1. LF UK, Praha
The introduction of proton pump´s inhibitors (PPIs) in clinical practice more than twenty years ago meant the most important progress in
the medicamentous therapy of inner medicine in 20th century. The rational use of PPIs has to be based on the understanding of PPIs clinical
pharmacology. Contrary to H2 antagonists the PPIs are administered once daily morning before breakfast. The combination with other
antiulcerous drugs are not recommended due to decreasing production of active PPIs metabolite. All PPIs are well tolerated and side effects
occur infrequently. Currently, a lot of discussion is focused on the drugs interaction between PPIs and antitrombotic drug clopidogrel. It
seems to be clear, that combination of PPIs with clopidogrel might be potential harmfull particularly in patients with high cardiovascular
risk due to significant inhibition of antitrombotic efficacy. In these patients new generation of PPIs should be considered.
Keywords: proton pump inhibitors, clopidogrel, pharmacokinetics
Published: October 1, 2011 Show citation
References
- Lukáš M, Ďuricová D. Inhibitory protonové pumpy. in: Remedia compedium. Čtvrté vydání. Panax Co, spol. s.r.o. 2009: 1-37.
- Schubert ML, Kaunitz JD. Gastric Secretion: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010 Elsevier s: 817-831.
Go to original source... - Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: What the practising physician needs to know. Drugs 2003; 63: 2739-2754. Go to original source...
Go to PubMed... - Kuipers E, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018. Go to original source... Go to PubMed...
- Richter JE, Friedenberg JK. Gastroesophageal Reflux Disease in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010 Elsevier s: 705-726. Go to original source...
- Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acidsuppression drugs. JAMA 2004; 292: 1955-1960. Go to original source... Go to PubMed...
- Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infections in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056. Go to original source... Go to PubMed...
- Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-326. Go to original source... Go to PubMed...
- Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P-450 activities. Drug Metab Dispos 2004; 32: 821-827. Go to original source... Go to PubMed...
- Bultas J. Význam kombinace klopidogrelu s inhibitory protonové pumpy. Čes a Slov Gastroent a Hepatol 2010; 64(4): 25-31.
- Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31(8): 810-823. Go to original source... Go to PubMed...
- Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 lossof-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56(2): 134-143. Go to original source... Go to PubMed...
- Hsu PI, Lai KH, Liu CP, et al. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140(3): 791-798. Go to original source... Go to PubMed...